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Abstract
Intrinsic antioxidant defences are important for neuronal longevity. We show that synaptic
activity, acting via NMDA receptor (NMDAR) signaling, boosts antioxidant defences through
changes to the thioredoxin-peroxiredoxin system. Synaptic activity enhances thioredoxin activity,
facilitates the reduction of overoxidized peroxiredoxins, and promotes resistance to oxidative
stress. Resistance is mediated by coordinated transcriptional changes: synaptic NMDAR activity
inactivates a novel FOXO target gene, the thioredoxin inhibitor Txnip. Conversely, NMDAR
blockade upregulates Txnip in vivo and in vitro, where it binds thioredoxin and promotes
vulnerability to oxidative damage. Synaptic activity also up-regulates the peroxiredoxin re-
activating genes Sestrin2 and Sulfiredoxin, via C/EBPβ and AP-1 respectively. Mimicking these
expression changes is sufficient to strengthen antioxidant defences. Trans-synaptic stimulation of
synaptic NMDARs is crucial for boosting antioxidant defences: chronic bath activation of all
(synaptic and extrasynaptic) NMDARs induces no antioxidative effects. Thus, synaptic NMDAR
activity may influence the progression of pathological processes associated with oxidative
damage.
Introduction
Oxidative stress occurs due to an imbalance between production of reactive oxygen species
(ROS) and the cell’s capacity to neutralize them through its intrinsic antioxidant defences.
Neurons are particularly susceptible to oxidative damage due to high levels of ROS
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production (through respiration and metabolism) and relatively low levels of certain
antioxidant enzymes, particularly catalase1, 2. Oxidative damage accumulates in normal
ageing and plays a role in the pathogenesis of several neurodegenerative diseases as well as
acute cerebrovascular disorders1, 2.
Regulation of cellular redox balance depends on the activity of antioxidant systems. Key
among these are the thiol reducing systems based round thioredoxin and glutathione, which
are important reducers of many oxidative stressors such as peroxides2, 3. The thioredoxin
system protects cells against H2O2-induced cell death, and its inhibition promotes oxidative
stress3. Thioredoxin-overexpressing mice display less oxidative brain damage following
ischemia and live longer3.
The thioredoxin system detoxifies peroxides by transferring reducing equivalents from
NADPH to peroxides via thioredoxin reductase, thioredoxin and peroxiredoxins (Prxs). Prxs
are a family of cytoprotective/antioxidative proteins4-6. The 2-Cys Prxs is the predominant
Prx subfamily, comprising Prx I-IV7. These Prxs contain a peroxidatic cysteine residue,
oxidized by peroxides to cysteine sulfenic acid (-SOH). Cys-SOH then forms a disulfide
bond with the resolving cysteine, which is in turn reduced by thioredoxin7. Sometimes,
under increased oxidative stress, Prx-SOH is further oxidized by peroxide to sulfinic (-
SO2H) or sulfonic (-SO3H) acid, causing inactivation of peroxidase activity8. Prx-SO2/3H is
not a substrate for the resolving cysteine and cannot be reduced by thioredoxin. As such, Prx
overoxidation to Prx-SO2/3H was thought to be irreversible. Recently, it has been found that
Prx-SO2/3H can be reduced back to the catalytically active thiol form by two ATP-
dependent reductases, sulfiredoxin8 and sestrin29. It is unknown whether neurons exhibit
the capacity to reduce overoxidized Prxs.
There is growing appreciation of the neuroprotective effects of synaptic activity10. In vitro
and in vivo studies revealed that part of this activity-dependent neuroprotection is mediated
by synaptic NMDAR activity11, 12. NMDAR blockade can trigger widespread neuronal
death- an effect which peaks in the first post-natal week in rats13. Newborn neurons of the
adult dentate gyrus also have a requirement for NMDAR activity in order to survive14.
Where NMDAR blockade does not kill neurons, it can make neurons vulnerable to
trauma15.
Despite the importance of neuronal antioxidant defences, little is known about whether they
are subject to dynamic regulation, or are a fixed function of neuronal type and age. This is
an important question: any regulation could influence biological ageing, or progression of
neurodegeneration. Here we study the influence of synaptic activity on the capacity of
neurons to deal with oxidative stress. We find that it exerts a profoundly positive effect,
mediated by a coordinated program of gene expression changes centred on the thioredoxin-
peroxiredoxin system.
Results
Synaptic NMDAR activity boosts antioxidant defences
P6 mice were injected with MK-801 which induced widespread TUNEL-positive cell death
in the cortex (Fig. 1a), as was reported for rat brains13. We next determined whether this
death was associated with oxidative stress. Following injection of MK-801 or vehicle,
cortical proteins were extracted and subjected to 2-D electrophoresis and protein carbonyl
levels assayed (a marker of oxidative damage). MK-801 triggered the carbonylation of many
cortical proteins (Fig. 1b,c). Thus, suppression of physiological NMDAR activity promotes
oxidative damage in the P6-7 cortex. We then investigated the influence of synaptic
NMDAR activity on cortical neuronal vulnerability to an oxidative insult (H2O2) in vitro.
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Blockade of spontaneous firing with TTX exacerbated H2O2-induced neuronal death (Fig.
1d), as did blockade of spontaneous NMDAR activity by MK-801 (Fig. 1d).
It is likely that most spontaneous NMDAR activity is synaptic, induced by spontaneous
firing, and not extrasynaptic (the culture media is glutamate-free). To investigate this we
performed analysis of open-channel blockade of NMDARs by MK-801 in current-clamped
neurons which revealed a reduction of 43±5% by 5 min which then plateaus (Fig. S1a (‘S’
denotes supplemental figure)). This current loss is blocked by TTX (Fig. S1b, compare
“activity block” with “TTX”), demonstrating that spontaneous NMDAR activity is
dependent on action potential (AP) firing, and so likely to be synaptic. To confirm this, we
blocked synaptic NMDARs using an established method of holding cells under voltage-
clamp in the presence of MK-801, TTX and zero Mg2+ 16. Spontaneous release of quanta of
glutamate activate synaptic NMDARs which are then blocked by MK-801. As with the
previous “activity block” protocol (Fig. S1a), the current that is antagonized using this
“quantal block” of synaptic NMDARs plateaus and goes no further (Fig. S1c,d,e). The
amount of current blocked using both protocols is similar (Fig. S1b). Furthermore, we
performed the “quantal block” protocol after the “activity block” protocol and found no
further loss of current (Fig. S1b). Thus, spontaneous NMDAR activity is predominantly
synaptic, and dependent on AP firing. Consistent with this, MK-801 + TTX combined did
not increase the amount of cell death beyond either drug alone (Fig. S1f), suggesting that
TTX and MK-801 are acting via a common pathway that stops spontaneous synaptic
NMDAR activity. As expected, MK-801 does not affect underlying firing activity (EPSC
frequency is unchanged, Fig. S1g): it is the activation of NMDARs promoted by that
underlying activity which is key to the antioxidative effect.
We then used the established method of network disinhibition to enhance synaptic activity,
by applying the GABAA receptor antagonist bicuculline, and the K+ channel antagonist 4-
aminopyridine (which enhances burst frequency, hereafter BiC/4-AP17). BiC/4-AP
treatment reduced H2O2-induced neuronal death (Fig. 1d), an effect blocked by TTX (Fig.
S1h) and also by MK-801 (Fig. 1d). BiC/4-AP treatment triggers activation of synaptic but
not extrasynaptic NMDARs17. Therefore the effect of MK-801 in inhibiting the BiC/4-AP-
induced neuroprotection is likely to be due to synaptic NMDAR blockade, as has been
demonstrated in recent publications17, 18. Note though that during H2O2 exposure, there
may be some extrasynaptic NMDAR activity due to dying cells releasing glutamate, which
would also be blocked by MK-801. However, experiments later firmly implicate synaptic
NMDARs as being responsible for the neuroprotective effect observed. As for other
potential routes of activity-dependent post-synaptic Ca2+ influx: blockade of L-type VGCCs
with nifedipine had a small effect on neuroprotection compared to MK-801 (Fig. S1i), while
blockade of N-type VGCCs with ω-conotoxin GVIA had no effect (Fig. S1j). Blockade of
P/Q-type VGCCs with ω-Agatoxin IVA abolished BiC/4-AP-induced firing (data not
shown), consistent with a role for these channels in presynaptic neurotransmitter release.
We corroborated our observations regarding the neuroprotective/antioxidative effects of
synaptic NMDAR activity using an alternative measure of cell viability: cellular ATP levels
(Fig. 1e). Also, an episode of BiC/4-AP-induced synaptic NMDAR activity that was
terminated before the addition of H2O2 was neuroprotective (Fig. 1f), indicating that long-
lasting transcriptional events may be involved. We hypothesized that synaptic activity
promotes the reduction/neutralization of cellular ROS following H2O2 exposure. We used
two fluorogenic ROS probes (2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) and
Dihydrorhodamine 123) to detect H2O2-induced ROS accumulation (Fig. 1g,h). MK-801-
treated neurons contained the highest levels of fluorescent (oxidized) forms of the probes
when challenged with H2O2, while BiC/4-AP-treated neurons exhibited the least. Thus,
H2O2-induced ROS accumulation is prevented by synaptic activity. H2O2-induced death in
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this model is apoptotic: it was prevented by the pan-caspase inhibitor qVD-Oph (fig. S1k).
Furthermore, H2O2 treatment triggers increased activity of both the initiator caspase 9 and
effector caspases 3/7, which was reversed by BiC/4-AP treatment (Fig. S1l).
Overwhelming of the thioredoxin system by oxidative trauma
Of the 2-Cys Prxs, mammalian neurons predominantly express PrxII, III and IV19.
Consistent with this, a pan-2-Cys Prx antibody detected 3 bands (Fig. S2a). To identify the
bands, we over-expressed PrxII, III and IV in turn and found enrichment of the bottom,
middle and upper endogenous band repectively (Fig. S2a), consistent with their theoretical
molecular weights.
The existence of overoxidized Prx-SO2/3H indicates an overwhelmed thioredoxin-
peroxiredoxin system. Western analysis using a Prx-SO2/3H-specific antibody revealed that
H2O2 caused Prx overoxidation in control and MK-801-treated neurons, while BiC/4-AP-
treated neurons displayed far less overoxidation (Fig. 2a). MK-801 decreased the effect of
BiC/4-AP (Fig. S2b). These differences were not due to BiC/4-AP-induced expression of
core components of the thioredoxin-peroxiredoxin system: levels of thioredoxin, thioredoxin
reductase and 2-Cys Prxs were unchanged by BiC/4-AP, or by MK-801 (Fig. 2b,c). To find
an alternative explanation, we performed microarray expression analysis on neurons
experiencing different levels of synaptic NMDAR activity. We searched for genes that were
regulated in opposite directions by enhancing/suppressing synaptic NMDAR activity in vitro
(BiC/4-AP vs. MK-801 treatment), and similarly regulated by NMDAR blockade in vivo.
We used mouse arrays, since they offered better annotation, and mouse cortical neurons
exhibited similar activity-dependent resistance to oxidative stress (data not shown).
Pro-oxidative Txnip is suppressed by synaptic activity
Seven genes were induced by BiC/4-AP treatment (in a MK-801-sensitive manner) which
were also suppressed by MK-801 in vitro and in vivo (supplemental table T1). One gene
exhibited negative regulation by synaptic NMDAR activity: Txnip (thioredoxin interacting
protein) which binds thioredoxin, inhibits its activity and promotes vulnerability to oxidative
stress3, 20, and was prioritized for further study. We confirmed NMDAR-dependent Txnip
regulation by q-RT-PCR in mouse (not shown) and rat cortical neurons (Fig. 2d) and by
western blot (Fig. 2e). A timecourse revealed Txnip expression to be dynamically regulated:
both rapidly suppressed by activity, and quickly up-regulated following activity blockade
with TTX (Fig. S2c). MK-801 and TTX combined did not induce Txnip more than either
drug alone (Fig. S2d), consistent with TTX acting by preventing spontaneous synaptic
NMDAR activity. Co-immunoprecipitation studies revealed that in MK-801-treated neurons
(high Txnip levels), Txnip is bound to thioredoxin (Fig. 2f) which would be expected to
inhibit thioredoxin activity. We measured thioredoxin enzyme activity in cell extracts taken
under low detergent conditions designed to preserve Txnip-thioredoxin interactions. Enzyme
activity in our cultures is almost entirely neuronal: glial cells contribute only 1-2.5 % of
thioredoxin activity (see supplemental methods). Consistent with an inhibitory effect of
Txnip, extracts from MK-801-treated neurons displayed lower levels of thioredoxin activity
than extracts from BiC/4-AP-treated neurons (Fig. 2g), despite equivalent thioredoxin
protein levels at 24 and 48 h (Fig. 2b and data not shown). To see whether Txnip renders
neurons vulnerable to oxidative stress we over-expressed it in synaptically active neurons,
with an eGFP marker to track neuronal fate. >99% of eGFP-expressing cells were NeuN-
positive, and <1% were GFAP-positive (data not shown). Expression of Txnip did not alter
BiC/4-AP induced bursting (Fig. S3a). By monitoring the neurons before and after H2O2
treatment, we found that Txnip expression reduced the antioxidative effects of synaptic
activity (Fig. 3a). Consistent with its known function, thioredoxin overexpression was
neuroprotective against a H2O2 insult (Fig. 3a). We corroborated the effect of Txnip using a
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different method of monitoring the viability of transfected neurons: co-expression of a
constitutively active luciferase expression construct (Fig. 3b). Thus, Txnip influences
neuronal antioxidant defences.
Cortical neuronal death induced by NMDAR blockade is developmentally regulated: at P0
none is observed but by P7 cell-death is widespread13, 21. We found that the coupling of
NMDAR blockade to Txnip up-regulation in vivo is similarly regulated. At P0, MK-801
does not induce an increase in Txnip, in contrast to P7 (Fig. 3c), suggesting that Txnip may
contribute to cell death at P7. The absence of an effect at P0 could be due to lower NMDAR
expression at this stage. We also investigated whether Txnip mRNA expression varies with
age in humans, and found elevated levels in the cortices from old individuals (81-95 yr)
compared to young (25-37 yr, Fig. 3d).
To determine whether suppressing Txnip expression is neuroprotective we investigated the
effect of siRNA-mediated knockdown. Validation of Txnip-directed siRNA was hampered
by the absence of a Txnip antibody which detects endogenous neuronal Txnip by
immunohistochemistry, and the fact that at this developmental stage siRNA transfection
efficiency is too low to analyze knock-down of endogenous protein by Western blot. Since
Txnip protein is sufficiently unstable that suppression of transcription is reflected at the
protein level after 24 h (Fig. 2e), we can reasonably assume that effective siRNA is able to
knock down endogenous protein levels in a similar timeframe. We expressed rat Txnip in
neurons and at 24 h found that co-transfection of two different Txnip-, but not control-
siRNA, blocked Txnip expression (Fig. 3e). Neither rat Txnip siRNA impaired expression of
transfected human Txnip (Fig. S3c) which contains 2 and 4 nucleotide differences (in central
regions) respectively from the corresponding rat sequence.
We found that Txnip siRNA did not significantly protect H2O2-exposed unstimulated
neurons (Fig. 3f) indicating, not surprisingly, that multiple transcriptional changes are
needed to mimic the antioxidative effect of synaptic NMDAR activity.
Induction of Prx-SO2/3H-reducing genes Sesn2 and Srxn1
To see whether overoxidized Prxs could be reduced in neurons, we applied a brief, high (200
μM) dose of H2O2 to induce Prx overoxidation and looked for recovery after H2O2 washout.
We focussed on PrxII, the major neuronal cytosolic Prx19. Both unstimulated and MK-801-
treated neurons exhibited no reduction in Prx-SO2/3H 16 h after washout (Fig. 4a). In
contrast, BiC/4-AP-treated neurons exhibited a large reduction in post-washout Prx-SO2/3H
levels (Fig. 4a). Thus, the degree of synaptic activity experienced can determine whether Prx
overoxidation is reversible, which may affect the efficacy of H2O2 detoxification by the
thioredoxin-peroxiredoxin system.
We next studied the transcriptional regulation of the two genes whose products mediate
reduction of Prx-SO2/3H: sulfiredoxin (Srxn1,8) and sestrin2 (Sesn29). BiC/4-AP strongly
induced Srxn1 and Sesn2 mRNA and protein expression (blocked by MK-801, Fig. 4b,c),
offering an explanation for the activity-dependent enhancement of Prx-SO2/3H-reducing
capacity (Fig. 4a). We hypothesized that up-regulation of Sesn2 and Srxn1 may cooperate
with the activity-dependent down-regulation of Txnip in promoting resistance to oxidative
insults. Overexpression of Sesn2 and Srxn1 in a cell-line (HEK293) that is amenable to high
efficiency transfection revealed that, following H2O2 treatment, Sesn2/Srxn1-coexpressing
cells have less Prx-SO2/3H than control cells (Fig. S4), in agreement with previous studies9,
22, 23. We then mimicked the three activity-dependent events described above by
transfecting expression vectors for Sesn2 and Srxn1 as well as Txnip siRNA. We found a
reduction in cell death following a H2O2 insult (Fig. 4d). Expression of Sesn2 and Srxn1
alone afforded variable protection that did not reach significance.
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We next performed experiments using siRNA targeted against Sesn2 and Srxn1. Activity-
dependent induction of Sesn2 expression was visualized by immunofluorescence, and two
siRNAs targeted against Sesn2 (siRNA(1) and (2)) knocked down expression (Fig. 4e).
Validation of Srxn1-directed siRNA was hampered by the absence of a Srxn1 antibody
which detects endogenous neuronal Srxn1 by immunohistochemistry. Instead, we
overexpressed Srxn1 plus a eGFP marker, and analyzed the effectiveness of the siRNA in
preventing Srxn1 expression, finding two which worked: siRNA(3) and (4), (Fig. 4f).
We paired the siRNAs (1/3 and 2/4) to test the effect of combined knockdown of Sesn2 and
Srxn1. BiC/4-AP-induced protection was diminished in neurons transfected with either pair
of siRNAs (Fig. 4g). We also tested the effect of these siRNA pairs on long-lasting
protection afforded by a prior episode of synaptic activity (Fig. 1f) and found a similar effect
(Fig. 4h). These experiments indicate that the combined changes in Txnip, Sesn2 and Srxn1
expression contribute to the enhancement of intrinsic antioxidant defences mediated by
synaptic NMDAR activity.
Txnip is a FOXO target gene
Since Txnip, Sesn2 and Srxn1 are novel activity-regulated genes, we wanted to understand
how they are regulated. Examination of the Txnip promoter revealed a conserved consensus
site for the Forkhead box O (FOXO) class of transcription factors (Fig. 5a). FOXOs undergo
nuclear export in response to Akt-dependent phosphorylation24 and Akt is activated by
synaptic NMDAR activity via phosphatidylinositol-3-kinase (PI3K18). Consistent with a
role for FOXOs, inhibition of PI3K with LY294002 elevated basal Txnip mRNA and
protein expression, and blocked activity-dependent suppression of Txnip (Fig. 5b). We next
cloned the Txnip promoter upstream of a luciferase reporter (Txnip-Luc) and introduced a
mutation into the putative FOXO binding site (Txnip(mut)-Luc). Txnip-Luc exhibited the
expected activity-dependent suppression (Fig. 5c), while Txnip(mut)-Luc exhibited lower
basal activity and did not undergo activity-dependent suppression (Fig. 5c). Overexpression
of the major neuronal FOXOs, FOXO1 or FOXO3a, enhanced Txnip-Luc promoter activity
but failed to activate Txnip(mut)-Luc (Fig. 5d). Thus, Txnip contains a functional FOXO
site which mediates activity-dependent inactivation of the promoter. Moreover, we found
that BiC/4-AP treatment triggered PI3K-dependent FOXO1 phosphorylation (Fig. 5e) and
nuclear export (Fig. 5f). In contrast, MK-801 enhanced nuclear localisation of FOXO1 (Fig.
5f). A mutant FOXO with its Akt phosphorylation sites mutated (FOXO-ADA25) did not
undergo activity-dependent export (data not shown). Chromatin-IP experiments revealed
that endogenous FOXO1 associates with the Txnip promoter in MK-801-treated neurons
more strongly than in BiC/4-AP-treated neurons (Fig. 5g,h). As a negative control,
chromatin-IP with a phospho-FOXO1 antibody failed to immunoprecipitate the Txnip
promoter (Fig. 5h). Consistent with the intermediate nature of the untreated neurons with
regard to Txnip expression and FOXO localisation, they exhibited variable FOXO promoter
occupancy: sometimes resembling MK-801-treated neurons and sometimes BiC/4-AP-
treated neurons (Fig. 5h left vs. right). These data support a model whereby synaptic activity
turns off Txnip ranscription by inducing the PI3K-Akt pathway, triggering FOXO
phosphorylation, dissociation from the Txnip promoter and export from the nucleus.
Sesn2 is a C/EBP target gene
We created a Sesn2-Luciferase reporter, which was activated by BiC/4-AP-induced
NMDAR activity (Fig. S5a). Deletion analysis identified the activity-inducible region
between -494 and -107 relative to the transcription start site (Fig. 6a). Further deletions
revealed that inducibility was conferred by 2 regions: -378 to -249 and -249 to -107 (data
not shown). In silico analysis revealed a potential binding site for the transcription factor
CCAAT enhancer binding protein (C/EBP) in each of these regions. Moreover, expression
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of an interfering mutant of C/EBP, ΔC/EBP26, inhibited activity-dependent induction of
Sesn2-Luc (Fig. 6b). Mutation of the proximal putative C/EBP site impaired activity-
dependent induction of Sesn2-Luc (Fig. 6c), while mutation of both sites abolished
induction (Fig. 6c). Thus, induction of Sesn2 by synaptic activity is mediated largely by C/
EBP.
Transcription of the Cebpb gene (but not Cebpa) is induced by BiC/4-AP stimulation (Fig.
6d, and data not shown), raising the possibility that this new expression may be important
for Sesn2 induction. Consistent with this, Sesn2 is not an immediate early gene: it was not
induced at 1 h (Fig. S5b), and induction at 4 h was severely inhibited by the protein
synthesis inhibitor cycloheximide (Fig. S5b). C/EBPβ is a CREB-regulated immediate early
gene27, induction of which is not inhibited by cycloheximide (Fig. S5c). The rapid
induction at 1 h contrasts with the slower induction of Sesn2, consistent with the
predominantly delayed-response nature of Sesn2 induction.
Srxn1 is an AP-1 target gene
We created a Srxn1-Luciferase reporter which was activated by BiC/4-AP-induced NMDAR
activity (Fig. S5a). Deletion analysis identified the activity-inducible region between -645
and -234 relative to the translation start site (Fig. 6e). Analysis of this region revealed two
putative AP-1 sites (TGAGTCA). Ca2+ signaling is known to activate AP-1 family
members, confirmed by our observation that BiC/4-AP stimulation activates a heterologous
AP-1 reporter 6.1 ± 0.61 fold (n=4). Overexpression of AP-1 (c-fos and c-jun) strongly
induced activity of the Srxn1 reporter, which was impaired when either putative AP-1 site
was mutated, and abolished in the double mutant (Fig. 6f). Moreover, mutation of either site
significantly reduced activity-dependent induction of the Srxn1 reporter construct, and the
double mutation abolished induction (Fig. 6g). Thus, Srxn1 is activated via AP-1 sites in its
promoter.
Extrasynaptic NMDARs fail to boost antioxidant defences
Trans-synaptic activation of synaptic NMDARs is anti-apoptotic, however, chronic
activation of all (synaptic and extrasynaptic) NMDARs by bath application of glutamate/
NMDA is not17. Moreover, synaptic vs. bath activation of NMDARs promote very different
transcriptional responses28. We tested whether trans-synaptic activation of synaptic
NMDARs is critical for NMDAR-dependent antioxidative effects, or whether bath
application of glutamate will suffice. We bath-applied a range of glutamate doses (up to the
toxicity threshold: 20 μM) in the presence of TTX to ensure that there was no preferential
activation of synaptic NMDARs, as can occur29. Stimulations were compared to control
(TTX only).
We first analysed bath-glutamate signaling to Akt, FOXO export, and Txnip suppression.
Sustained glutamate exposure only triggered transient Akt activation (Fig. 7a) and weak
FOXO export (Fig. 7b). Suppression of Txnip expression was poor compared to BiC/4-AP
stimulation (Fig. 7c). Also, no dose of bath glutamate induced either Sesn2 or Srxn1
appreciably (Fig. 7d,e) nor was there significant induction of Sesn2’s activator, Cebpb (Fig.
7f). Consistent with this, glutamate did not promote the reduction of overoxidized Prxs (Fig.
7g,h), nor induce protection against H2O2-induced death (Fig. 7i). Thus, the strong
antioxidative effect of NMDAR signaling is restricted to the trans-synaptic activation of
synaptic NMDARs, and is not a pre-conditioning-type effect in response to sub-toxic
glutamate exposure.
We next investigated whether these differences are due to NR2 subunit differences between
synaptic and extrasynaptic NMDARs, since NR2A-containing NMDARs may be enriched at
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synaptic locations30 and signal to neuroprotection more effectively than NR2B-containing
NMDARs31. Both whole-cell NMDAR currents and extrasynaptic NMDAR currents
(analyzed by blocking synaptic NMDARs with the “quantal block” protocol, Fig. S1c) were
blocked by 70% by the NR2B antagonist ifenprodil (Fig. 8a). Ifenprodil does not completely
block responses even when mediated exclusively by NR2B-containing NMDARs (around
80 % is achieved32). Thus, synaptic and extrasynaptic NMDARs are overwhelmingly and
equally NR2B-dominated, a likely consequence of the relatively early developmental stage
under study.
We hypothesized that both harmful and protective consequences of NMDAR activation in
these neurons would be inhibited by NR2B antagonists. Both ifenprodil and Ro 25-6981
protected neurons from cell death induced by a toxic dose of NMDA (50 μM, Fig. 8b).
NR2B antagonists also impaired protective signaling by trans-synaptic activation of synaptic
NMDARs: ifenprodil and Ro 25-6981 exacerbated neuronal death by H2O2 (Fig. 8c), caused
an up-regulation of Txnip (Fig. 8d), reduced BiC/4-AP induced protection against H2O2-
induced death (Fig. 8e) and reduced signaling to Sesn2 and Srxn1 activation (Fig. 8f). Thus,
differences in the effect of synaptic stimulation vs. bath application of agonist are unlikely to
be due to large, clear-cut differences in NR2 subunit composition at synaptic and
extrasynaptic sites. However, we cannot rule out a role for NR2A-containing NMDARs at
the synapse-this would require analyses of NR2A-null neurons.
Memantine is an open channel blocker with a fast off-rate. Its uncompetitive nature results
in an effective blockade of chronic NMDAR activity caused by bath-applied glutamate33.
However, due to its fast off-rate and voltage-dependent binding properties, memantine does
not substantially interfere with normal synaptic NMDAR activity by accumulating in the
channel33. In the context of this study, memantine appears suited to the sparing of the
antioxidative effects of trans-synaptic activation of synaptic NMDARs, while blocking
chronic activation of NMDARs by low level glutamate which does not enhance antioxidant
defences (Fig. 7i).
Memantine (at 5 μM or 10 μM) blocks NMDAR-dependent neuronal death induced by 50
μM NMDA (Fig. 8g). However, it does not interfere with trans-synaptic NMDAR-
dependent activation of antioxidant defenses: unlike MK-801, memantine does not
exacerbate H2O2-induced death (Fig. 8h) nor promote nuclear localisation of FOXOs (Fig.
8i) or Txnip expression (Fig. 8j), and does not interfere with synaptic activity-dependent
signaling to Sesn2 and Srxn1 activation (Fig. 8k,l) nor Txnip suppression (Fig. 8m), nor
activity-dependent neuroprotection against H2O2 (Fig. 8n). We also assessed the effects of
memantine administration in vivo at a dose (20 mgkg-1) consistently shown to be
therapeutically active in protecting against ischemic insults 34 and known to result in brain
concentrations of memantine similar to those used in our in vitro experiments35. Unlike
MK-801, memantine injection does not cause neuronal apoptosis in the P7 cortex: no death
was observed either by TUNEL-staining (Fig. 8o) or Fluorojade staining, which labels
degenerating neurons irrespective of mechanism of death (data not shown). The differential
effects of MK-801 and memantine emphasize that trans-synaptic stimulation of synaptic
NMDARs is important for boosting antioxidant defences and that blockade of synaptic
NMDARs boosts vulnerability to oxidative stress in vitro and in vivo.
Overoxidation of peroxiredoxins by ischemia/reperfusion
We wanted to determine whether the thioredoxin system becomes overwhelmed in an in
vivo model of neuronal death. We chose ischemia/reperfusion as a model to study, since it is
associated with an acute wave of oxidative damage that affects a significant population of
neurons and is implicated in the pathological process1. We subjected adult mice to 60 min
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MCAO and examined extracts from cortical regions at 4 h post-reperfusion, which is prior to
development of the infarct.
Increased Prx-SO2/3H formation in the MCA territory (cortex and striatum) following
ischemia/reperfusion is evident, compared to equivalent samples from the sham-operated
individuals (Fig. 9). The profile of overoxidation is subtly different from that of in vitro
H2O2 treatment: PrxIII is overoxidized to a greater extent by ischemia/reperfusion than by
H2O2 treatment. Thus, Prx-SO2/3H formation does occur in vivo in response to brain insult,
indicating that the thioredoxin-peroxiredoxin system is overwhelmed. This lends added
relevance to our findings concerning the regulation of genes whose products can influence
this system.
Discussion
We have demonstrated that neuronal antioxidative defences are subject to activity-dependent
enhancement, mediated by synaptic NMDAR signaling. A coordinated program of gene
expression changes with a net antioxidative effect underlies this enhancement. The changes
described centre on the thioredoxin-peroxiredoxin system, and involve hitherto
uncharacterized activity-regulated genes.
Txnip promotes oxidative stress and cell death
Txnip interacts with the reduced form of thioredoxin, inhibits its biochemical activity and
sensitizes a variety of cell types to H2O2-induced death3, 20. Txnip is implicated in the
pathogenesis of diabetes: it is up-regulated in the vasculature and pancreatic beta cells of
diabetic rats and is induced by hyperglycaemia in both systems, promoting oxidative
stress20, 36. Txnip plays a role in oncology: it is proposed to suppress tumour cell growth
and metastasis, and reduced levels have been observed in a variety of cancers3. Txnip’s
influence on neuronal vulnerability to oxidative stress is consistent with its role as a pro-
oxidative gene in non-neuronal systems.
Studies on transcriptional control by synaptic Ca2+ signals focus almost exclusively on up-
regulated genes. Results here concerning the regulation of Txnip expression demonstrate
that gene inactivation must also be considered. Our findings that Txnip is regulated by
FOXOs adds to our knowledge of FOXO-regulated pro-death genes, which thus far have
focussed mainly on Bim and Fasl24, 37.
Peroxiredoxins are cytoprotective antioxidant enzymes
Prxs are a family of thiol-based antioxidants with cytoprotective effects in the face of
oxidative insults. PrxII protects cortical neurons against Aβ toxicity38 and oxygen-glucose
deprivation 39. Interfering with PrxII expression renders neuroblastoma cells vulnerable to
oxidative stress5, and renders cortical neurons vulnerable to MPP+ 6. PrxIII protects
hippocampal neurons against excitotoxicity4.
Low reported catalytic rates for Prxs led to the suggestion that Prxs would not be able to
compete with catalase or glutathione peroxidases for cellular peroxide, despite evidence of
the antioxidative properties of Prxs. This apparent paradox was due to an underestimation of
peroxidase rates of mammalian PrxII, as a result of their indirect calculation by measuring
NADPH oxidation rates which measure regeneration by the thioredoxin system. When
peroxide levels are high, it is clear that the thioredoxin system cannot keep up. In fact, when
rates of mammalian Prx were measured directly40 they were found to be 100 fold greater
than previously thought, similar to rates recently found in PrxI and II from S. cerevisiae41.
Since Prxs are relatively abundant, they are likely to play an important antioxidant role in
mammalian in vivo systems.
Papadia et al. Page 9
Nat Neurosci. Author manuscript; available in PMC 2008 October 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Thus, molecular events that render Prxs inactive in vivo in pathological scenarios may
contribute to disease progression. We observe Prx-inactivating Prx-SO2/3H formation
following cerebral ischemia in vivo (Fig. 9), but this is not the only way by which Prxs can
be inhibited: The enzymic activity of PrxII can be impaired by cdk5-mediated
phosphorylation6 and by nitrosylation42, both of which occur in Parkinson’s Disease6, 42.
Re-activation of Prx-SO2/3H by Sulfiredoxin and Sestrin2
Sulfiredoxin was initially characterized in yeast43 and then in mammalian cells 8 and acts
by catalysing the ATP-dependent formation of a sulfinic acid phosphoric ester on Prx8
which is then reduced by thiol equivalents such as thioredoxin. The mechanism of ATP-
dependent Sesn2 is unknown9. The capacity of neurons to reduce inactive Prx-SO2/3H was
hitherto unknown, and our findings show that active neurons have a far greater capacity for
this than inactive neurons, and are associated with high levels of Srxn1 and Sesn2. This is
the first time that Prx-SO2/3H reducing activity has been found to be signal-dependent.
Given the widespread expression of these genes, this raises the question as to whether the
Prx-SO2H reduction process is signal-inducible in vivo. For example, ischemic
preconditioning is associated with activation of AP-144 which could therefore result in up-
regulation of Srxn1 expression and reduce Prx-SO2/3H formation that occurs following
ischemia (Fig. 9).
Activity-dependent regulation of antioxidant defences
It is not clear why synaptic activity, acting via Ca2+ signaling, should act to boost
antioxidant defences. One possibility is to protect against increased ROS generation:
electrical activity and its downstream physiological consequences are expensive
energetically and metabolically. ROS are generated as a by-product of respiration and many
metabolic pathways, so the regulation of antioxidant defences may be a homeostatic
mechanism to ensure the correct redox balance in the neuron. However, results described
here show that the effects of synaptic activity go beyond protecting against increased
endogenous ROS production, since it renders neurons resistant to an exogenously applied
insult.
An implication of our work is that a neuron’s lifelong pattern of activity may influence its
accumulation of oxidative damage and ultimately its longevity during ageing, or affect the
progression of pathological processes associated with oxidative damage such as AD or PD.
This raises the question as to whether altered patterns of neuronal activity in vivo, in
response to changes in behaviour or environment, can alter neuronal antioxidative capacity.
Rodent environmental enrichment (EE) is neuroprotective and modulates onset and severity
of models of AD and Huntington’s disease, while in humans, a cognitively stimulating
lifestyle may reduce risk of AD and PD45, 46. It is an intriguing possibility that EE may,
through altered or increased patterns of neuronal activity, result in increased antioxidant
defences in those brain regions that are more intensively used. We find that only 5 minutes
of BiC/4-AP induced burst activity significantly induce Srxn1 expression (by 40%, Fig. S6a)
and induce down-regulation of Txnip (by 60%, Fig. S6b), raising the possibility that modest
episodes of elevated activity in vivo may trigger significant changes.
NMDAR blockade can trigger widespread neuronal death- an effect which peaks in the first
post-natal weeks in rats. NMDAR blockade does not kill adult neurons outright13.
Consistent with this, carbonyl assay of cortical proteins from MK-801 injected adult mice
(Fig. S7) revealed no significant increases in carbonylation of any proteins (in sharp contrast
to the P7 cortex, Fig. 1b) although there was a trend towards an increase in carbonylation in
several spots. NMDAR blockade in the adult CNS can exacerbate death in response to
metabolic inhibition or traumatic brain injury 11, 15. The borderline effects of MK-801 in
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the adult cortex with regard to oxidative stress (Fig. S7) may translate to more substantial
increases when the brain is subject to an additional trauma, and contribute to the increased
neuronal death observed 11, 15.
The growing understanding of the neuroprotective effects of physiological synaptic
NMDAR activity, coupled with its established role in synaptic plasticity, suggests that
global NMDAR antagonism may not be appropriate as a anti-excitotoxic or anti-apoptotic
therapeutic strategy12, 47. Memantine is a NMDAR antagonist approved for AD, and unlike
conventional antagonists, has properties suited to sparing trans-synaptic activation of
synaptic NMDARs, while blocking continuous low level NMDAR activation by chronic
glutamate exposure33. This enhancement of physiological signal over pathological noise is
thought to improve plastic processes at the synapse and prevent apoptosis caused by chronic
low level activation of NMDARs33. In our hands, memantine is able to prevent NMDAR-
dependent excitotoxic cell death, while not inhibiting the antioxidative effects of trans-
synaptic activation of synaptic NMDARs. These findings are consistent with memantine’s
clinically tolerated mechanism of action33.
The ageing human brain is associated with an accumulation of oxidative damage2. Elevated
levels of Txnip expression in the ageing human cortex (Fig. 3d) may be a consequence of
lowered levels of activity and could conceivably influence vulnerability to oxidative stress.
The situation is exacerbated in AD sufferers, where Txnip levels are further elevated48, as
are levels of FOXO1 and FOXO3a mRNA48, activators of Txnip (Fig. 5). Whether any of
these expression changes represents a contributing factor to pathogenesis, or merely an
epiphenomenon, is not clear. Nor is it clear whether expression of Srxn1 or Sesn2 are altered
in neurodegenerative diseases. An understanding of the signals and genes that control
neuronal antioxidant defences may point the way to therapeutic strategies aimed at slowing
neurodegeneration in a variety of disorders associated with oxidative damage.
Experimental Procedures
See Supplemental Methods file (SuppMethods.doc) for further information.
Neuronal cultures, stimulation, and the induction of oxidative stress
Cortical rat neurons were cultured as described 18 from E21 rats or E17 mouse pups in
Neurobasal-A medium and B27 (Invitrogen). Stimulations and transfections (Lipofectamine
2000, Invitrogen) were done at DIV8-10 after transferring neurons into trophically-deprived
medium 18. Action potential bursting was induced by treatment with 50 μM bicuculline,
plus 250 μM 4-aminopyridine (Sigma) to enhance burst frequency. Stimulations were
initiated 12 h prior to the application of an oxidative insult. Neurons were fixed after a
further 24 h and subjected to DAPI staining and cell death quantified by counting (blind) the
number of apoptotic nuclei as a percentage of the total. For details of analysis of peroxide-
induced ROS accumulation and caspase activity, see supplemental methods.
Electrophysiological recording and analysis
Currents were recorded (at 21±2°C) using an Axopatch-1C amplifier (Molecular Device,
Union City, CA). Data were digitized and analyzed using WinEDR v6.1 software (John
Dempster, University of Strathclyde, UK). Neurons were voltage-clamped at -70 mV, and
recordings were rejected if the holding current was >-100 pA or if the series resistance
drifted by >20% of its initial value (<35 MΩ). See supplemental methods for details of
solutions, drugs and of “activity block” and “quantal block” protocols
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Gene expression analysis by qPCR and microarray
For qPCR, cDNA was synthesized from 1-3 μg RNA (extracted using Qiagen Rneasy kit)
using the Stratascript QPCR cDNA Synthesis kit and qPCR performed in an Mx3000P
QPCR System (Stratagene) using Brilliant SYBR Green QPCR Master Mix. For detailed
protocols and primer sequences, see supplemental methods. For microarray-based
expression analysis, total RNA was quality-confirmed on RNA 6000 Nanochips in the
Agilent 2100 Bioanalyzer. Purified biotinylated target cRNA was produced (see
supplemental methods) and hybridized to Mouse Genome 430A plus 2.0 microarrays
(Affymetrix). After hybridization, the arrays were washed and scanned (Genechip Scanner
3000, Affymetrix). Expression was calculated using the robust multiarray average algorithm
implemented in the Bioconductor (http://www.bioconductor.org) extensions to the R
statistical programming environment.
In vivo procedures
In vivo MK-801 and memantine administration, TUNEL histology, and protein carbonyl
assay of extracted proteeins were all performed using established techniques. In vivo focal
cerebral ischemia was performed on adult male C57Bl/6J mice under an appropriate Home
Office Licence. See supplemental methods section for details of all in vivo procedures.
Other experimental procedures and materials
Neuronal transfections, following the fate of transfected cells, luciferase assays,
immunofluorescencent staining, western blotting, chromatin immunoprecipitation, co-
immunoprecipitation and thioredoxin enzyme assays all involved standard protocols (see
supplemental methods section for these and information on plasmids, siRNA and
antibodies).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Synaptic NMDAR activity promotes resistance to oxidative insults and prevents ROS
accumulation
A) TUNEL-positive apoptosis in the cortex of P7 mice subjected to IP-injection of MK-801
at P6 (exposure for 24 h). Quantitation (upper) and representative sections (lower-scale bar
200 μm). B,C) Analysis of carbonyl content of 2-D separated proteins from the cortices of
P7 mice subjected to IP-injection of MK-801. Blotted 2-DE gels were stained with silver
staining to reveal protein spots (right). C) Comparison of intensity of representative protein
spots *p<0.05 (n=6) 2-tailed T-test (in this and subsequent cases unless stated). D) Cell
death due to 24 h H2O2 insult in the face of the indicated treatments, applied 12 h before
insult. BiC/4-AP stimulation is labelled as “BiC” in this and subsequent figures. (Lower)
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Examples pictures, scale bar=40 μm. *p<0.05 compared to control H2O2 treated (n=4),
mean ± s.e.m shown in this and all cases. E) Cell death measured by analyzing ATP levels.
Treatments as for (D). *p<0.05 compared to control, H2O2 treated, n=3. F) Cell death due to
24 h H2O2 insult in the face of the indicated treatments, applied 12 h before insult. All
activity was terminated prior to H2O2 exposure (by TTX + MK-801). *p<0.05 compared to
control (H2O2 treated), n=4. G,H). ROS accumulation following H2O2 treatment and in
control conditions measured within neurons treated as indicated. Two ROS probes used as
indicated. Fluorescence levels were normalized to cell number (as measured using the
Celltiter Glo assay, Promega, *p<0.05, n=5).
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Fig. 2. Synaptic activity prevents the overoxidation of peroxiredoxins in response to an oxidative
insult, and negatively regulates the Thioredoxin inhibitor Txnip
A) Western analysis of Prx overoxidation using an anti-PrxSO2/3H specific antibody.
Analysis normalized to appropriate Prx band intensity. *p<0.05 compared to control, H2O2-
treated neurons (n=5). Note for upper (PrxIV) band, a higher exposure is often taken to more
accurately assess loading (as is the case in the example shown). B,C) Thioredoxin,
Thioredoxin reductase and 2-Cys Prx levels analyzed by Western blot after 24 h of the
indicated treatments (n=3). D) q-RT-PCR of Txnip RNA from rat cortical neurons treated as
indicated (this and all subsequent q-RT-PCR data are normalized to Gapdh levels. *p<0.05
compared to control (n=4)). E) Western analysis of Txnip protein expression in response to
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the indicated treatments (24 h, *p<0.05 compared to control, n=3). This and all quantitation
of Western blots involves normalisation to β-tubulin or other suitable control (such as Akt in
the case of Pi-Akt, Prx in the case of PrxSO2/3H). F) Co-immunoprecipitation of
Thioredoxin with an anti-Txnip antibody in samples from neurons experiencing different
levels of synaptic NMDAR activity for 24 h (*p<0.05, n=5). G) Thioredoxin activity
(insulin-reducing assay) in neurons treated with MK-801, expressed as a % of the activity
observed in BiC/4-AP-treated neurons (*p<0.05 compared to BiC-stimulated neurons, n=6).
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Fig. 3. Txnip and Thioredoxin can regulate neuronal vulnerability to oxidative stress
A) Loss of GFP-positive neurons expressing Txnip, Thioredoxin (Txn) or control plasmid
(beta-globin) in the face of 24 h 100 μM H2O2. *p<0.05 (n=4). B) Neurons transfected with
a constitutively active vector (SV40-Luc) and Txnip or control plasmid, treated with BiC/4-
AP prior to oxidative insult for 24 h, followed by luciferase activity measurement *p<0.05
(n=5). C(left) q-RT-PCR of Txnip mRNA expression in the murine cortex in vivo in
response to MK-801 treatment at P0 and P7. *p<0.05 (n=4). C(right) Western blot showing
up-regulation of Txnip protein in the cerebral cortex of individual mice in vivo by MK-801
treatment of P7 mice. Each lane represents a different mouse. D) RNA from post-mortem
human frontal cortices was extracted and TXNIP mRNA abundance assessed by quantitative
RT-PCR. TXNIP is shown normalized to GAPDH and 28S, as their expression in the frontal
cortex does not change significantly with age49(n=16). E) Neurons transfected with rTxnip
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plus control or one of two Txnip-directed siRNAs. Protein harvested at 24 h and subjected to
Western analysis for Txnip protein. Untransfected sample (U/T) shown for comparison. F)
Loss of GFP-positive neurons transfected with control or one of two Txnip siRNAs in the
face of 24 h 100 μM H2O2. Scale bar 40 μm. Data from 4 independent experiments.
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Fig. 4. Synaptic activity promotes reduction of Prx-SO2/3H and induces neuroprotective
expression of the Prx-SO2/3H-reducing genes Sesn2 and Srxn1
A) Recovery of PrxII-SO2/3H following a 1 h exposure to high H2O2 (200 μM). Neurons
stimulated as indicated for 12 h prior to H2O2 exposure. Washout period was 16 h (*p<0.05
compared to pre-washout level, n=5). B,C) q-RT-PCR of Sestrin2 (Sesn2, B) and
Sulfiredoxin (Srxn1, C) in response to the indicated treatments (BiC stimulation: 4 h).
*p<0.01 (n=7). Lower panels show regulation of Sesn2 and Srxn1 protein. D) H2O2-induced
loss of GFP-positive neurons transfected as indicated. Scale bar 60 μm.*p<0.05 (one-way
ANOVA followed by Fisher’s LSD post-hoc test for this and subsequent siRNA
experiments, n=4). Right panels show example pictures (arrows indicate transfected neurons
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whose fate is studied, Scale bar 60 μm). E) Effect of control- or Sesn2-directed siRNA on
BiC/4-AP (24 h) induced Sesn2 expression. F) Effect of control- or Srxn1-directed siRNA
on production of rat Srxn1 driven from an expression vector. G) Effect of knock-down of
Sesn2 and Srxn1 on activity-dependent protection against an oxidative insult. Neurons were
transfected with control siRNA or one of two pairs of siRNAs which target both Sesn2 and
Srxn1. Neurons were stimulated where indicated with BiC/4-AP and then treated with 100
μM H2O2.. *p<0.05 unpaired T-test (n=4). H) Effect of knock-down of Sesn2 and Srxn1 on
long-lasting activity-dependent protection. Experimental details as for (G) except that BiC/
4-AP-induced synaptic activity was terminated after 12 h by the addition of TTX + MK-801.
After this, the oxidative insult (100 μM H2O2) was applied. *p<0.05 (n=6).
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Fig. 5. Txnip is a FOXO target gene
A) Schematic showing conservation of a FOXO binding site in the proximal 5′ promoter
region of Txnip, positions given relative to start of protein coding region (NB. 5′UTR is 222
nt long). B) PI3K inhibition by LY294002 (30 μM) induces Txnip expression, and
suppression of Txnip protein and mRNA expression by BiC treatment is blocked by
LY294002 *p<0.05 compared to control (n=3). C) Txnip-Luc and Txnip-(mut)-Luc (FOXO
site mutated) activity assayed 16 h after the indicated treatments (n=5). In all reporter
assays, firefly luciferase based reporter signal is normalized to expression of a cotransfected
renilla luciferase control plasmid, pTK-RL. D) Txnip-Luc and Txnip-(mut)-Luc activity
assayed in neurons co-transfected with Control or FOXO expression plasmids. *p<0.05
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compared to control plasmid (n=3-5). E) Western analysis of FOXO1 phosphorylation in
response to the indicated treatments (30 min stimulation, example Western shown below
analysis). *p<0.05 compared to control (n=3). F) Subcellular distribution of transfected
myc-tagged FOXO1 analyzed by immunofluorescence (examples on the right; scale bar 30
μm.). G,H) Chromatin immunoprecipitation with an anti-FOXO1 antibody, followed by
PCR of the Txnip promoter region containing the consensus FOXO binding site (compared
to PCR of the input). (G) shows analysis of ChIP band intensity (Normalized to input)
relative to MK-801-treated neurons *p<0.05 (n=5). (H) shows example individual ChIP
experiments, with (H, right) showing an anti-phospho-FOXO1 negative control ChIP.
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Fig. 6. Sesn2 is a C/EBP target gene, Srxn1 is an AP-1 target gene
All experiments performed in cortical neurons. A) Deletion analysis of a luciferase-based
reporter of the Sesn2 promoter. B) Effect of an interfering mutant of C/EBP on activity-
dependent induction of the Sesn2 reporter construct. *p<0.05 compared to control plasmid
(n=5). C) Effect of putative C/EBP binding site mutation on activity-dependent induction of
the Sesn2 promoter (distal site ATTTCACACC mutated to ATTTCGGCCC; proximal site
TTTGCAGCATC mutated to TTTGCGGCCTC). NB. C/EBP sites have consensus (A/
T)TTGCG(C/T)AA(C/T), although quite substantial variations are tolerated50. D) q-RT-
PCR of C/EBPβ induction by synaptic activity at 4 h (n=6). E) Deletion analysis of a
luciferase-based reporter of the Srxn1 promoter. F) Effect of AP-1 (cfos+cjun) expression on
activity of the Srxn1 reporter construct, both wild-type and that containing mutations in the
two putative AP-1 binding sites (distal site TGAGTCA mutated to TAAGCTT, proximal
site TGAGTCA mutated to TGGGCCC). G) Effect of AP-1 site mutation on activity-
dependent induction of the Srxn1 promoter.
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Fig. 7. Extrasynaptic NMDARs do not promote antioxidative effects
A) Phospho-(Serine 473)-Akt kinetics in cortical neurons in response to a range of glutamate
concentration (normalized to Akt levels, n=3). The dashed line indicates the level of
phospho-Akt induced by BiC/4-AP treatment at 2 h. Example Western also shown. B)
Subcellular distribution of transfected myc-tagged FOXO1 analyzed by
immunofluorescence, and stimulated as indicated for either 30 min or 2 h (n=3). C-F) q-RT-
PCR of the indicated genes in response to a range of glutamate concentrations (4 h
stimulation). Dashed line indicates the level of expression following 4 h BiC/4-AP
stimulation (n=3). G,H) Lack of recovery of PrxII-SO2/3H following a 1 h exposure to high
[H2O2] (200 μM). Neurons treated with glutamate for 12 h prior to H2O2 exposure.
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Washout (w/o) period is 16 h. Prx-SO2/3H levels normalized to Prx loading (n=3). I) Cell
death due to 24 h H2O2 insult in the face of the indicated glutamate treatments, applied 12 h
before insult (n=3).
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Fig. 8. Memantine, but not NR2B antagonists, discriminate between pro-survival and pro-death
NMDAR signaling
A) Ifenprodil (3 μM) sensitivity of whole-cell and extrasynaptic currents (n=8) isolated
using the “quantal block” protocol. B) Cell-death induced by 1 h exposure to 50 μM NMDA
± NMDAR antagonists MK-801 (10 μM), ifenprodil (3 μM), Ro 25-6981 (500 nM) *p<0.05
(n=3). C) Cell death due to 24 h H2O2 in the face of the indicated treatments, applied 12 h
before insult. *p<0.05 (n=4). D) Txnip mRNA expression in neurons treated as indicated (24
h). *p<0.05 (n=3). E) Cell death due to 24 h H2O2 in the face of the indicated treatments.
*p<0.05 (n=3). F) Effect of ifenprodil on BiC/4-AP induction of Sesn2-Luc and Srxn1-Luc.
*p<0.05 (n=4). G) Effect of memantine (5 or 10 μM) on NMDA (50 μM)-induced cell
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death. *p<0.05 compared to control NMDA treatment (n=3). H) Cell death due to 24 h H2O2
insult in the face of the indicated treatments. *p<0.05 (n=3). I) Subcellular distribution of
transfected myc-tagged FOXO1 analyzed by immunofluorescence. J) Txnip mRNA
expression in neurons treated for 24 h as indicated. K-M) Effect of memantine on BiC/4-AP-
induced changes in Sesn2 (K), Srxn1 (L) and Txnip (M) expression (n=3). N) Effect of
memantine on BiC/4-AP-induced protection against H2O2 treatment. O) TUNEL analysis of
the cortex of P7 mice subjected to IP-injection of memantine (20 mgkg-1) at P6 (for 24 h,
n=6). Dotted line indicated the level of death observed with MK-801 injection (Fig. 1a).
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Fig. 9. An ischemic episode, followed by reperfusion, induces overoxidation of peroxiredoxins
Western analysis of Prx-SO2/3H formation in homogenate from the MCA territory (cortex
and striatum) of mice subjected to 60 min MCAO followed by 3 h reperfusion, compared to
the equivalent region from sham-operated mice. Analysis (left) of the Western (right) of 6
ischemic and 5 control samples.
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